ALACHUA, Fla.--(BUSINESS WIRE)--RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, is celebrating 40 years of sterilizing human allografts through the Tutoplast® process. Since the first clinical use in 1971, there has been zero incidence of allograft associated infections from more than a million implants sterilized through the process.
The Tutoplast process is a chemical sterilization methodology originally developed by Tutogen Medical, GmbH in Neunkirchen, Germany, which merged with RTI in February 2008, to sterilize and preserve tissue for implantation. Membrane and soft tissue augmentation grafts, as well as bone particulate, sterilized through Tutoplast are used in dental, urological and other procedures.
“We are extremely proud of our clinical history of Tutoplast-sterilized implants, a track record that is unmatched in the industry today in terms of longevity," said Robby Lane, General Manager of Tutogen Medical, GmbH. "Patient safety is a top priority for our company, and proven sterilization of biologic tissue allows us to provide safe human and animal tissue for use in a variety of surgeries.”
About Tutogen Medical, GmbH
Tutogen Medical, GmbH is the Germany-based organization of RTI Biologics that processes allograft and xenograft implants for global distribution. Tutogen Medical has more than 40 years of experience in providing safe, high quality biologic implants for surgeons and their patients worldwide.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.